Filing Details
- Accession Number:
- 0001396814-24-000085
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-06-13 18:15:15
- Reporting Period:
- 2024-06-12
- Accepted Time:
- 2024-06-13 18:15:15
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1396814 | Pacira Biosciences Inc. | PCRX | Pharmaceutical Preparations (2834) | 510619477 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1545439 | Lauren Riker | C/O Pacira Biosciences, Inc. 5401 West Kennedy Boulevard, Suite 890 Tampa FL 33609 | Senior Vice President, Finance | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-06-12 | 21,360 | $0.00 | 42,045 | No | 4 | A | Direct | |
Common Stock | Disposition | 2024-06-12 | 3,970 | $28.72 | 38,075 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Footnotes
- Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2025, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.33 to $29.32, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3.